To the Editor: Meningococcal disease in US military personnel is controlled by vaccines, the first of which was developed by the US Army (1) (2) (3) (4) (5) . In 1985, the quadrivalent polysaccharide vaccine (MPSV-4) was implemented as the military standard. It was replaced during 2006-2008 by the quadrivalent conjugate vaccine (MCV-4). Every person entering US military service is required to receive this vaccine.
Meningococcal disease incidence in active-duty US military personnel, historically far above that in the general population (6), has decreased >90% since the early 1970s, when the first vaccine was introduced (7) . Over the last 5 years, incidences in the military and US general populations have become equivalent (8) . Here we update previously published data (8) from the Naval Health Research Center's Laboratory-based Meningococcal Disease Surveillance Program of US military personnel. Data-gathering methods and laboratory analyses of samples from personnel suspected of having meningococcal disease have been previously described (8) Results of these comparisons are subject to several limitations. First, because the relative proportions of the 2 vaccines changed, a differential effect of herd immunity caused by one or the other could have differentially suppressed rates. Second, along with the decrease in the MPSV-4 population, the average time from vaccination increased relative to the period in which MPSV-4 was given, concomitant with decreasing immunogenicity. Any elevated incidence in the MPSV-4-vaccinated population since 2006 could be associated with time since vaccination. Third, the same factors involved in the decline in incidence in the US general population that began in ≈2001 might be at play in the military, confounding the vaccine effects. Fourth, as the rate of vaccine coverage in the US population increased, a higher proportion of recruits might have entered the military already vaccinated; thus, their military vaccination was essentially a booster.
Meningococcal disease incidence decreased during 2000-2013. Our data suggest that cases in MCV-4-vaccinated personnel are similar to those in MPSV-4-vaccinated personnel, regardless of whether the incidence calculation includes cases caused by serogroup B (nonvaccine covered). More extensive study is needed to confirm the relative effects of the vaccines (10) . Serogroup B accounted for 5 of the 8 cases during 2012-September 2014), and prevention of disease caused by this serotype remains a challenge.
